Reactivation of a developmental Bmp2 signaling center is required for therapeutic control of the periosteal niche in the murine skeleton

  1. Valerie S Salazar
  2. Luciane P Capelo
  3. Claudio Cantù
  4. Dario Zimmerli
  5. Nehal Gosalia
  6. Steven Pregizer
  7. Karen Cox
  8. Satoshi Ohte
  9. Marina Feigenson
  10. Laura Gamer
  11. Jeffry S Nyman
  12. David J Carey
  13. Aris Economides
  14. Konrad Basler
  15. Vicki Rosen  Is a corresponding author
  1. Harvard School of Dental Medicine, United States
  2. Universidade Federal de São Paulo, Brazil
  3. University of Zürich, Switzerland
  4. Regeneron Pharmaceuticals, United States
  5. Vanderbilt University Medical Centre, United States
  6. Geisinger Health System, United States

Abstract

Two decades after signals controlling bone length were discovered, the endogenous ligands determining bone width remain unknown. We show that postnatal establishment of normal bone width in mice, as mediated by bone-forming activity of the periosteum, requires BMP signaling at the innermost layer of the periosteal niche. This developmental signaling center becomes quiescent during adult life. Its reactivation however, is necessary for periosteal growth, enhanced bone strength, and accelerated fracture repair in response to bone-anabolic therapies used in clinical orthopedic settings. Although many BMPs are expressed in bone, periosteal BMP signaling and bone formation require only Bmp2 in the Prx1-Cre lineage. Mechanistically, BMP2 functions downstream of Lrp5/6 pathway to activate a conserved regulatory element upstream of Sp7 via recruitment of Smad1 and Grhl3. Consistent with our findings, human variants of BMP2 and GRHL3 are associated with increased risk of fractures.

Data availability

The DiscoverEHR human dataset is published and publicly available at http://www.discovehrshare.com. Using search terms 'BMP2' and 'GRHL3' and a Bonferroni significance threshold of P < 1.86e-7 for 268,192 association results, we observed three significant associations for BMP2 and six significant associations for GRHL3.Mouse limb bud ChIP-sequencing data are available through ArrayExpress website https://www.ebi.ac.uk/arrayexpress and accession #E-MTAB-7652.

The following data sets were generated

Article and author information

Author details

  1. Valerie S Salazar

    Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2111-9313
  2. Luciane P Capelo

    Instituto de Ciência e Tecnologia, Universidade Federal de São Paulo, São José dos Campos, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  3. Claudio Cantù

    Institute for Molecular Life Sciences, University of Zürich, Zürich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  4. Dario Zimmerli

    Institute for Molecular Life Sciences, University of Zürich, Zürich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  5. Nehal Gosalia

    Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Steven Pregizer

    Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Karen Cox

    Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Satoshi Ohte

    Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Marina Feigenson

    Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Laura Gamer

    Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Jeffry S Nyman

    Department of Orthopaedic Surgery and Rehabilitation, Vanderbilt University Medical Centre, Nashville, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. David J Carey

    Geisinger Health System, Danville, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Aris Economides

    Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6508-8942
  14. Konrad Basler

    Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  15. Vicki Rosen

    Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
    For correspondence
    vicki_rosen@hsdm.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4029-1055

Funding

National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR055904)

  • Vicki Rosen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: In vivo experiments were performed in compliance with the Guide for the Care and Use of Laboratory Animals and were approved by the Harvard Medical Area Institutional Animal Care and Use Committee (protocol #04043 to Vicki Rosen).

Copyright

© 2019, Salazar et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,291
    views
  • 388
    downloads
  • 27
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Valerie S Salazar
  2. Luciane P Capelo
  3. Claudio Cantù
  4. Dario Zimmerli
  5. Nehal Gosalia
  6. Steven Pregizer
  7. Karen Cox
  8. Satoshi Ohte
  9. Marina Feigenson
  10. Laura Gamer
  11. Jeffry S Nyman
  12. David J Carey
  13. Aris Economides
  14. Konrad Basler
  15. Vicki Rosen
(2019)
Reactivation of a developmental Bmp2 signaling center is required for therapeutic control of the periosteal niche in the murine skeleton
eLife 8:e42386.
https://doi.org/10.7554/eLife.42386

Share this article

https://doi.org/10.7554/eLife.42386

Further reading

    1. Cell Biology
    Jittoku Ihara, Yibin Huang ... Koichi Yamamoto
    Research Article

    Chronic kidney disease (CKD) and atherosclerotic heart disease, frequently associated with dyslipidemia and hypertension, represent significant health concerns. We investigated the interplay among these conditions, focusing on the role of oxidized low-density lipoprotein (oxLDL) and angiotensin II (Ang II) in renal injury via G protein αq subunit (Gq) signaling. We hypothesized that oxLDL enhances Ang II-induced Gq signaling via the AT1 (Ang II type 1 receptor)-LOX1 (lectin-like oxLDL receptor) complex. Based on CHO and renal cell model experiments, oxLDL alone did not activate Gq signaling. However, when combined with Ang II, it significantly potentiated Gq-mediated inositol phosphate 1 production and calcium influx in cells expressing both LOX-1 and AT1 but not in AT1-expressing cells. This suggests a critical synergistic interaction between oxLDL and Ang II in the AT1-LOX1 complex. Conformational studies using AT1 biosensors have indicated a unique receptor conformational change due to the oxLDL-Ang II combination. In vivo, wild-type mice fed a high-fat diet with Ang II infusion presented exacerbated renal dysfunction, whereas LOX-1 knockout mice did not, underscoring the pathophysiological relevance of the AT1-LOX1 interaction in renal damage. These findings highlight a novel mechanism of renal dysfunction in CKD driven by dyslipidemia and hypertension and suggest the therapeutic potential of AT1-LOX1 receptor complex in patients with these comorbidities.

    1. Cell Biology
    Qi Zeng, Chen Yao ... Shuai Chen
    Research Article

    Mounting evidence has demonstrated the genetic association of ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) gene polymorphisms with bronchial asthma and a diverse set of inflammatory disorders. However, its role in type I interferon (type I IFN) signaling remains poorly defined. Herein, we report that ORMDL3 is a negative modulator of the type I IFN signaling by interacting with mitochondrial antiviral signaling protein (MAVS) and subsequently promoting the proteasome-mediated degradation of retinoic acid-inducible gene I (RIG-I). Immunoprecipitation coupled with mass spectrometry (IP-MS) assays uncovered that ORMDL3 binds to ubiquitin-specific protease 10 (USP10), which forms a complex with and stabilizes RIG-I through decreasing its K48-linked ubiquitination. ORMDL3 thus disrupts the interaction between USP10 and RIG-I, thereby promoting RIG-I degradation. Additionally, subcutaneous syngeneic tumor models in C57BL/6 mice revealed that inhibition of ORMDL3 enhances anti-tumor efficacy by augmenting the proportion of cytotoxic CD8 positive T cells and IFN production in the tumor microenvironment (TME). Collectively, our findings reveal the pivotal roles of ORMDL3 in maintaining antiviral innate immune responses and anti-tumor immunity.